Ask AI

Augmentation Treatments for Major Depressive Disorder

Clinical Thought
Clinical Thought

Released: November 12, 2026

See Activity Collection

Incomplete response to antidepressant treatment and persistent residual symptoms remain challenges in managing major depressive disorder. This ClinicalThought explores strategies for optimizing, switching, or augmenting antidepressant therapy, including approved second-generation antipsychotics, emerging pharmacologic options, and interventional treatments. Learn how symptom profiles, treatment response, and tolerability can guide individualized treatment decisions.

MDD Treatment Augmentation


First-line antidepressant pharmacotherapies for major depressive disorder (MDD) outperform placebos for symptom reduction, but their shortcomings include relatively modest effect sizes,1 incomplete degrees of both symptomatic and functional recovery, and frequent residual symptoms even among responders. Residual symptoms impair psychosocial functioning2 and increase the risk for full depression relapse.3 Symptoms most often involve sleep disruption and low energy,4,5 attentional and cognitive complaints,5-7 and anhedonia.4,8 Before interpreting an incomplete response as treatment resistance, healthcare professionals should confirm an adequate medication trial and adherence. Adverse effects, cost, stigma, concerns about dependence, and limited access to follow-up can undermine treatment exposure and subsequent nonresponse. Additional factors that contribute to apparent nonresponse include diagnostic validity, psychiatric and medical comorbidities, and the fit between treatment and symptom targets. Prominent anxiety may complicate treatment and prolong the time required for improvement.

Decisions to optimize, switch, or augment treatment should reflect the degree of clinical benefit already achieved. Preserving a tolerated, partially effective antidepressant while adding an evidence-supported intervention may avoid losing existing gains. Switching may be preferable when the original treatment demonstrates limited efficacy or causes adverse effects that outweigh its therapeutic benefits. Escalating antidepressant doses beyond established therapeutic ranges does not reliably convert nonresponders to responders.9 Approximately one third of adults with MDD do not significantly improve after adequate trials of 2 or more conventional antidepressant medications.10 Furthermore, successive treatment failures reduce the likelihood of remission,11 supporting timely consideration of alternative strategies.

Second-generation antipsychotics have received growing attention as a first-line adjunctive treatment option to augment incomplete response to traditional antidepressants for major depression. FDA-approved agents include aripiprazole, brexpiprazole, cariprazine, quetiapine XR, and lumateperone. Selection requires balancing efficacy against adverse effects, including akathisia, sedation, weight gain, and metabolic effects. Recent meta-analyses based on randomized trials reveal no significant differences in efficacy across such agents, but differences exist in relative rankings of magnitude of effect and tolerability.12,13

Other options address particular residual symptoms or clinical circumstances. The novel D3 dopamine agonist pramipexole has emerging “off-label” evidence for treatment-resistant depression14 and anhedonia15 but requires monitoring for nausea, somnolence, orthostasis, and impulse control. Adjunctive modafinil may exert “off-label” antidepressant properties when added to a monoaminergic antidepressant, particularly to target fatigue and excessive sleepiness16 as well as executive dysfunction and other cognitive symptoms.17 Lithium and thyroid hormone remain additional augmentation options for some patients, although modern studies augmenting contemporary antidepressants are limited. These uses require attention to their evidence base, off-label status, interactions, and appropriate monitoring. Evidence concerning cognitive symptoms includes vortioxetine18 and selected adjunctive approaches, although studies specifically targeting residual cognitive complaints in patients with otherwise improved depression remain limited.

For more resistant illness, FDA-approved options include combination olanzapine/fluoxetine and intranasal esketamine. Current evidence supports consideration of interventional strategies such as intravenous ketamine, electroconvulsive therapy, repetitive transcranial magnetic stimulation (and a novel protocol called intermittent theta-burst stimulation), and vagus nerve stimulation. Comparative findings require interpretation within the populations and settings studied. Adjunctive esketamine demonstrated superior outcomes compared with adjunctive quetiapine XR in patients with MDD who had only a partial response to a traditional antidepressant.19 This study represents one of the few head-to-head studies showing superiority of a novel agent to an adjunctive atypical antipsychotic with established antidepressant effects.

Throughout treatment, measurement-based assessment should be combined with shared decision-making. The goal is sustained improvement in symptoms and functioning through a coherent, tolerable regimen that reflects the patient’s priorities and preferences.

REFERENCES

  1. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252-260.
  2. Kennedy N, Paykel ES. Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord. 2004;80:135-144.
  3. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50:97-108.
  4. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60: 221-225.
  5. McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011;31:180-186.
  6. Semkovska M, Quinlivan L, O’Grady T, et al. Cognitive function following a major depressive episode: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6:851-861.
  7. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011;41:1165-1174.
  8. Whiston A, Lennon A, Brown C, et al. A systematic review and individual patient data network analysis of the residual symptom structure following cognitive-behavioral therapy and escitalopram, mirtazapine and venlafaxine for depression. Front Psychiatry. 2022;13:746678.
  9. Rink L, Braun C, Bschor T, et al. Dose increase versus unchanged continuation of antidepressants after initial antidepressant treatment failure in patients with major depressive disorder: a systematic review and meta-analysis of randomized, double-blind trials. J Clin Psychiatry. 2018;79:17r11693.
  10. McIntyre RS, Alsuwaidan M, Baune BT, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22:394-412.
  11. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917.
  12. Cutler AJ, Lemyre A, Zhang Q, et al. Efficacy and safety of lumateperone and other atypical antipsychotics approved as adjunctive treatment for major depressive disorder in the United States: a network meta-analysis. Adv Ther. 2026;43:4079-4103.
  13. McIntyre RS, Stahl SM, Shim RS, et al. Adjunctive antipsychotics in major depressive disorder: a systematic review and network meta-analysis. JAMA Psychiatry. 2026;83:741-750.
  14. Browning M, Cowen PJ, Galal U, et al. Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK. Lancet Psychiatry. 2025;12:579-589.
  15. Ventorp F, Asp M, Olsson S, et al. Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial. Nat Med. 2026;32:2570-2578.
  16. Goss AJ, Kasser M, Costafreda SG, et al. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74:1101-1107.
  17. Vaccarino SR, McInerney SJ, Kennedy SH, et al. The potential procognitive effects of modafinil in major depressive disorder: a systematic review. J Clin Psychiatry. 2019;80:19r12767.
  18. McIntyre RS, Harrison J, Loft H, et al. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016;19:pyw055.
  19. Reif A, Bitter I, Buyze J, et al. Esketamine nasal spray versus quetiapine for treatment-resistant depression. N Engl J Med. 2023;389:1298-1309.

Your Thoughts
What is your greatest challenge in treating MDD that does not respond sufficiently to the first 2 treatments tried? Join the conversation by commenting below and learn more about MDD adjuncts with our ongoing program!

Poll

1.

What is your greatest challenge in treating MDD that does not respond sufficiently to the first 2 treatments tried?

Submit